Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 4,345 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Time Management Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

NCT02968719
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil TDS Version A, Donepezil TDS Version B, Aricept, Donepezil TDS Version D, Donepezil TDS Version E
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Nov 10, 2026, 1:37 AM EST
Completed Not applicable Interventional Results available

Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT03641378
View directory record Official record
Conditions
Stem Cell Transplant
Interventions
Palliative Care Intervention, Standard Transplant Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Nov 10, 2026, 1:37 AM EST
Completed Phase 2 Interventional

Study That Tests AD109 in Patients Taking GLP-1 Drugs

NCT06400615
View directory record Official record
Conditions
OSA
Interventions
AD109
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Anniston, Alabama • Jacksonville, Florida • Monroe, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Nov 10, 2026, 1:37 AM EST
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

NCT02101385
View directory record Official record
Conditions
Malignant Neoplasm of Breast, Breast Cancer
Interventions
Genomically Directed Monotherapy, Observation/Standard Therapy
Drug · Other
Lead sponsor
Bryan Schneider, MD
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
29
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 10, 2026, 1:37 AM EST
Completed Not applicable Interventional

Effect of Occupational Therapy in Promoting Medication Adherence

NCT03551925
View directory record Official record
Conditions
Hypertension, Diabete Type 2
Interventions
Treatment as Usual Plus Occupational Therapy, Treatment as Usual
Behavioral
Lead sponsor
University of Indianapolis
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Nov 10, 2026, 1:37 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants

NCT03614455
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Milademetan, Itraconazole, Posaconazole
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Nov 10, 2026, 1:37 AM EST
Recruiting Phase 4 Interventional

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

NCT07569926
View directory record Official record
Conditions
Prostate Cancer
Interventions
fluciclovine (18F)
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 1:37 AM EST
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)

NCT07681778
View directory record Official record
Conditions
Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA)
Interventions
OPGx-RDH12
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
4
States / cities
Phoenix, Arizona • Philadelphia, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 10, 2026, 1:37 AM EST
Completed Not applicable Interventional Results available

Program of Intensive Support in Emergency Departments for Care Partners of Cognitively Impaired Patients

NCT03325608
View directory record Official record
Conditions
Dementia
Interventions
POISED Care
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
75 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Nov 10, 2026, 1:37 AM EST
Completed Not applicable Interventional Results available

Patient and Provider Interventions for Managing Osteoarthritis in Primary Care

NCT01130740
View directory record Official record
Conditions
Osteoarthritis
Interventions
Osteoarthritis Intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Nov 10, 2026, 1:37 AM EST
Recruiting Not applicable Interventional

Oral Health Intervention for Caregivers of Children Presenting for Dental Surgery

NCT07220850
View directory record Official record
Conditions
Early Childhood Caries
Interventions
Behavioral Treatment
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
Up to 7 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 10, 2026, 1:37 AM EST
Enrolling by invitation Phase 2 Interventional

The Unique and Combined Effects of Prenatal and Early Childhood Programming on Child Maltreatment: Examining Mechanisms of Change

NCT06732310
View directory record Official record
Conditions
Child Abuse, Intimate Partner Violence, Secondary Prevention, Parenting
Interventions
Pregnant Moms' Empowerment Program, Reminiscing and Emotion Training, Pregnancy - Active Control, Enhanced Case Management
Behavioral
Lead sponsor
University of Notre Dame
Other
Eligibility
3 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Notre Dame, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 10, 2026, 1:37 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Nov 10, 2026, 1:37 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

NCT03482960
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon gas, PFP
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Nov 10, 2026, 1:37 AM EST
Completed No phase listed Observational

Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis

NCT01974804
View directory record Official record
Conditions
Brain Cancer
Interventions
MRI
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Nov 10, 2026, 1:37 AM EST
Completed Not applicable Interventional Results available

Combined Technology Enhanced Home Exercise Program and Other Non-pharmacological Intervention for Cancer Survivors

NCT03576274
View directory record Official record
Conditions
Cancer-related Problem/Condition, Exercise, Acupressure
Interventions
Technology Enhanced Home Exercise (TEHE), Auricular Point Acupressure (APA), Mindfulness body scan (MBI)
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Nov 10, 2026, 1:37 AM EST
Recruiting Not applicable Interventional

The Fundamental Adaptive Skills Training

NCT07140718
View directory record Official record
Conditions
Fundamental Adaptive Skills Training, Relaxation and Mindfulness Training
Interventions
Fundamental Adaptive Skills Training, Relaxation and Mindfulness Training
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 10, 2026, 1:37 AM EST
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Nov 10, 2026, 1:37 AM EST
Terminated Phase 1 Interventional

Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock

NCT02716597
View directory record Official record
Conditions
Shock, Septic
Interventions
25% Albumin, Placebo
Drug
Lead sponsor
Alexander Flannery, 859-323-4011
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Nov 10, 2026, 1:37 AM EST
Terminated Phase 4 Interventional

Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control

NCT00744250
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Cystic Fibrosis
Interventions
Pancrelipase
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Nov 10, 2026, 1:37 AM EST
Recruiting Not applicable Interventional

Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health

NCT06587204
View directory record Official record
Conditions
Heart Diseases
Interventions
Control Group, Decentralized Group, Digital Literacy Navigation Group, Social Care Navigation Group
Other · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 10, 2026, 1:37 AM EST
Completed Phase 2 Interventional Results available

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

NCT01265433
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF
Biological
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 10, 2026, 1:37 AM EST
Completed Not applicable Interventional

Mindfulness App Training for Cardiovascular Health

NCT06152185
View directory record Official record
Conditions
Cardiovascular Diseases, Mindfulness
Interventions
Mindfulness Training, Enhanced Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 10, 2026, 1:37 AM EST
Completed Not applicable Interventional

A Pilot Proof of Concept Study of the Effects of Administration of SCFA in Rheumatoid Arthritis (EASi-RA)

NCT05152615
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Short Chain Fatty Acids (SCFA) Dietary Supplement
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Nov 10, 2026, 1:37 AM EST